Tenoxicam

In response to the long-term management needs of chronic inflammatory pain, the iteration of non-steroidal anti-inflammatory drugs has always been centered on "the balance between analgesic effect and gastrointestinal safety". As an enolic acid class selective cyclooxygenase inhibitor, tenoxicam exerts long-acting anti-inflammatory, analgesic and antipyretic effects by inhibiting the synthesis of prostaglandins. Compared with similar drugs, it has a half-life of 40 to 70 hours, and only once-daily administration is required to maintain a stable plasma concentration. Clinically, it is mainly used for symptom control of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis, and can also relieve moderate to severe pain caused by postoperative pain, acute gout and soft tissue injury, especially suitable for middle-aged and elderly patients who require long-term analgesia and have poor medication compliance.

The global tenoxicam market size was approximately USD 120 million in 2023, and it is expected to grow steadily at a compound annual growth rate of 2.1% from 2024 to 2030. The growth momentum mainly comes from the rising prevalence of osteoarthritis under the background of population aging and the improvement of drug accessibility in emerging markets. Currently, generic drugs dominate the market, and Europe and India are the main API supply regions. The domestic market is currently in the introduction stage, has not yet been included in the national centralized procurement catalog, and there is no publicly verifiable local market size data.

The original research enterprise of tenoxicam is Roche, and the original brand name is "Tilcotil". The core compound patents in major markets such as Europe and the United States expired around 2000. The main dosage forms approved by the original research include tablets (20mg), injections (20mg) and suppositories (20mg), among which the 20mg tablet has been included in the FDA Reference Listed Drug Catalog, but has not been included in the Chinese *Catalog of Reference Preparations for Chemical Drugs*. As of the retrieval time point, there is no approved tenoxicam registration number with A status on the API registration platform of China NMPA Center for Drug Evaluation (CDE). A small number of domestic enterprises have submitted marketing applications for tenoxicam oral preparations, which have not yet been approved for formal production. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of tenoxicam impurity reference standards, supporting the full-process needs of API R&D and quality research. Most products are in stock, and in-stock orders placed before 16:00 can be shipped on the same day. All reference standards comply with the compliance requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA, and can meet the testing standards for domestic and foreign registration and declaration.